Board summary
Key figures
39,674
Registered population
62.2% aged 18–64
17.8%
Aged 65+
ICB 18.8% · England 17.9%
20.8%
Ethnic minority (non-White)
12.6% Asian · England 9.6%
0.7%
In IMD quintile 1
ICB 0.8% · England 21.0%
~290
Core20 residents (est.)
Resident basis; registered basis ~262 · see page 3
5,802
Hypertension register
+7.33% in 3 yrs · England +5.60%
328
SMI register
36.9% of Spelthorne's
502
COPD register
Reviews +1.82% in 3 yrs
Forecast to 2030
7,425
Hypertension patients, 2030
+1,623 on today
76.6%
QRISK ≥20% on statins, 2030
+5.36pp over 3 yrs
4.7%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Smoking cessation support offers fell over three years.
Recorded smoking support offered fell 8.5 pp over 2023 to 2025 to 88.4% (Spelthorne 95.1%, ICB 94.3%, England 94.2%, +0.1 pp).
Wide practice variation in vaccination and phone access.
QOF vaccination achievement spans 37.3 pp from Virginia Water Medical Practice (34.6%) to Grove Medical Centre (71.9%), alongside a 38.4 pp phone-access range.
Annual review achievement exceeds national and local benchmarks.
Annual reviews exceed England for heart failure at 85.0% (England 78.5%), COPD at 89.8% (England 76.4%), and asthma at 84.0% (England 65.7%).
Population, age and ethnicity
Projected population growth of 8.8% outpaces England while Asian residents reach 12.6%
SASSE NETWORK 2 PCN registers 39,674 patients. Those aged 65+ comprise 17.8% (7,074 patients; Spelthorne 17.4%, NHS Surrey Heartlands Integrated Care Board 18.8%, England 17.9%). Children aged 0-17 represent 20.0% (7,933 patients; Spelthorne 20.3%, ICB 20.4%, England 19.6%). Projected list growth to 2030 is 8.8% (methodology unverified). Census data for associated areas shows Asian residents comprise 12.6% (Spelthorne 12.8%, ICB 7.7%, England 9.6%) and White residents 79.2% (Spelthorne 78.7%, ICB 85.3%, England 81.1%).
Age profile
65+: ICB 18.8%, England 17.9%
Ethnicity
Older people · falls rows are Spelthorne local-authority (LA) data, not PCN
| Measure | Local | South East | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Spelthorne LA) | 1,875 | 2,018 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 85.8% | 82.2% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 56.6% | 57.8% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Spelthorne LA) | 950 | 981 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Spelthorne LA) | 10.7 | 14.0 | 14.8 | 2022‑24 |
Deprivation and Core20
Core20 deprivation is 0.7% overall and concentrated entirely within Grove Medical Centre
SASSE NETWORK 2 PCN's Core20 share is 0.7% (Spelthorne 1.8%, NHS Surrey Heartlands Integrated Care Board 0.8%, England 21.0%), with an average IMD decile of 7.4 (England 5.5). Registered Core20 patients concentrate at Grove Medical Centre (1.8% share, 262 estimated patients), whereas the other four practices record 0.0%. Resident models estimate about 290 people in deciles 1 and 2 (52 aged 0-17), though resident estimates do not reconcile directly with registered lists. Core20 outreach should focus on Grove Medical Centre rather than dispersing resources network-wide.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
328
SMI register
0.80% recorded prevalence
167
Learning disability register
0.41% recorded prevalence
12
Care homes, 614 beds
In the PCN catchment
8.6%
Provide unpaid care
Spelthorne, Census 2021
The PCN records 167 patients on the learning disability register (0.4%; Spelthorne 0.4%, NHS Surrey Heartlands Integrated Care Board 0.5%, England 0.6%) and 328 on the severe mental illness register (0.8%; Spelthorne 0.8%, ICB 0.8%, England 1.0%). The catchment contains 12 care homes with 614 beds. Crude register prevalence does not establish unmet need or under-detection, which would require clinical record audits to assess, alongside care home coordination.
Severe mental illness: physical health checks
Severe mental illness prevalence is 0.8% (England 1.0%). Published checks show 83.5% blood pressure (England 83.4%) and 82.7% BMI (England 82.1%); unmeasured elements cannot imply completion. Smoking support offered fell 8.5 pp (England +0.1 pp) to 88.4% (England 94.2%).
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,802
Hypertension register
+7.33%
Register growth, 3 yrs
Spelthorne +4.33% · England +5.60%
+3.71pp
BP control, under 80
≤140/90 · +3.22pp aged 80+
+1,623
More patients by 2030
Forecast 7,425 (16.36%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.2% (5,802 patients), below Spelthorne (15.7%) and England (15.2%), though practice rates range from 13.0% at Knowle Green Medical to 16.3% at Virginia Water Medical Practice. Over 2023 to 2025, prevalence rose 1.0 pp (England +0.8 pp). While 91.1% of patients have a recent blood pressure reading (England 90.0%), blood pressure control under age 80 is 66.2%, trailing England (67.8%) and NHS Surrey Heartlands Integrated Care Board (68.1%), whereas control at age 80+ reaches 80.9% (England 81.2%). Observation periods for registers were not supplied. Blood pressure control in patients under 80 trails national benchmarks despite high testing coverage, indicating an opportunity to prioritise clinical treatment intensification.
Lipids and statins
Statin therapy reaches 64.3% in patients with QRISK ≥ 20% (England 63.6%) and 86.7% for diabetes with cardiovascular disease (England 84.4%), though CKD uptake is 69.8% (England 70.3%). With lipid therapy exceeding England benchmarks across primary and secondary prevention, the PCN can prioritise closing the small treatment gap in chronic kidney disease.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 54,159 | £2.10 | £2.24 | £1.86 | £113,734 |
| Cardiovascular (all), 2025 | 69,802 | £4.36 | £4.74 | £3.33 | £304,337 |
In 2026, the PCN prescribed 54,159 lipid-modifying items at £2.10 per item (spend £113,734). The PCN spent £7,582 less than at NHS Surrey Heartlands Integrated Care Board's unit cost (£2.24), but £12,998 more than at England's unit cost (£1.86). Higher unit costs relative to England suggest an opportunity to examine lipid-modifying formulary choices.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+6.45%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+4.20%
Asthma prevalence, PCN 3-yr % change
COPD recorded prevalence is 1.2% (502 patients), below England (1.9%), Spelthorne (1.5%), and NHS Surrey Heartlands Integrated Care Board (1.3%), with three-year prevalence falling 0.5% (England +2.6%). However, COPD annual reviews reach 89.8%, above England (76.4%) and Spelthorne (85.9%). Similarly, asthma prevalence is 5.2% (1,993 patients), below England (6.6%), but reviews reach 84.0% (England 65.7%), leaving an estimated 319 patients without a recorded review. High review achievement alongside lower prevalence is consistent with strong care processes for registered patients.
Cancer register and children's immunisation
Cancer prevalence is 4.0% (1,618 patients), above England (3.8%) but below NHS Surrey Heartlands ICB (4.5%). For childhood immunisations, 6-in-1 coverage at 12 months reaches 96.2% (exceeding the 95.0% target). However, age-five cohorts trail: MMR dose 1 is 92.3% and dose 2 is 88.5% (a 3.8 pp difference, below target by 6.5 pp), while 4-in-1 booster coverage is 85.4% (below target by 9.6 pp).
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
61.4%
Surrey Heartlands ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~650
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Surrey Heartlands ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Prostate | 65.7% | 53.2% | 18% | 1,044 |
| Breast | 88.2% | 85.4% | 27% | 798 |
| Bowel | 48.1% | 47.0% | 18% | 626 |
| Lung | 33.2% | 33.8% | 17% | 497 |
| Skin cancer | 89.8% | 87.8% | 19% | 384 |
In 2022, 61.4% of cancers with a known stage in NHS Surrey Heartlands ICB (2,955 of 4,810) were diagnosed at stage 1 or 2, above England (55.3%) but 13.6 percentage points below the 75.0% national ambition by 2028, representing about 650 extra early-stage cases a year. Staging coverage was 67.7% (4,810 of 7,106 registered cancers). Early-stage shares ranged from 88.2% in breast (704 of 798) and 76.7% in cervix (23 of 30) to 48.1% in bowel (301 of 626) and 33.2% in lung (165 of 497); site-specific small numbers warrant caution. PCN cervical screening coverage is 69.4% (England 66.8%), though Knowle Green Medical records 65.9%.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026 (provisional), Ashford and St Peter's Hospitals NHS Foundation Trust achieved 76.4% on the cancer 62-day referral to treatment standard, 8.6 percentage points below the 85.0% standard, trailing The Hillingdon Hospitals NHS Foundation Trust (84.0%) and Frimley Health NHS Foundation Trust (81.8%), but above NHS Surrey and Sussex Integrated Care Board (71.5%) and England (71.2%). The trust met the 28-day faster diagnosis standard at 85.5% (standard 75.0%). Diagnostic 6+ week waits at the trust were 49.6% for colonoscopy (England 30.8%) and 28.4% for non-obstetric ultrasound (England 19.6%).
| Pathways within standard (%) | Ashford and St Peter's | Hillingdon | Frimley Health | Surrey and Sussex ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 85.53 | 79.63 | 87.95 | 79.29 | 79.32 |
| 31-day treatment (96%) | 94.21 | 96.67 | 92.89 | 90.45 | 92.50 |
| 62-day referral to treatment (85%) | 76.38 | 84.05 | 81.84 | 71.51 | 71.16 |
| Diagnostic waits over 6 weeks (%) | Ashford and St Peter's | Hillingdon | Frimley Health | England |
|---|---|---|---|---|
| MRI | 0.09 | 3.99 | 12.85 | 21.40 |
| CT | 9.27 | 3.21 | 0.63 | 9.92 |
| Echocardiography | 0.97 | 0.92 | 3.35 | 28.48 |
| Colonoscopy | 49.61 | 26.58 | 22.84 | 30.83 |
| Gastroscopy | 56.74 | 26.56 | 7.43 | 29.02 |
| All 15 DM01 tests | 23.12 | 10.98 | 7.49 | 23.14 |
| Community services activity | Surrey residents | Surrey and Sussex ICB |
|---|---|---|
| Care contacts | 109,530 | 309,615 |
| Referrals | 28,700 | 66,930 |
| Patients with a contact | 33,510 | 85,660 |
Community services (residents of Surrey), Jun 2026 (provisional). In June 2026 (provisional), Community Services Dataset activity shows that 69.6% of contacts with borough residents (76,215 of 109,530 contacts) were with adults aged 65 and over. These data reflect activity across Spelthorne residents rather than PCN-specific cohorts, highlighting that older adults account for the large majority of local community-service provision.
Practice variation and patient experience
Phone access spans 38.4 pp and vaccination achievement spans 37.3 pp across practices
Overall 2025/26 QOF achievement ranges from 81.7% at Knowle Green Medical to 95.1% at Fordbridge Medical Centre against 92.5% in England. Clinical achievement reaches 100.0% at Fordbridge Medical Centre, but vaccination and immunisation achievement varies across practices by 37.3 pp, from 34.6% at Virginia Water Medical Practice to 71.9% at Grove Medical Centre (England 55.2%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Orchard | 123 | 0.0 | 74.3% | 79.1% | 91.4% |
| Knowle Green | 92 | 0.0 | 64.1% | 78.2% | 79.7% |
| Virginia Water | 108 | 0.0 | 61.1% | 78.0% | 79.6% |
| Grove | 109 | 1.8 | 41.8% | 68.7% | 76.6% |
| Fordbridge | 118 | 0.0 | 35.9% | 80.1% | 72.4% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Dementia prevalence fell 9.7% while heart failure reviews rose 19.3% over three years
Over 2023 to 2025, dementia recorded prevalence fell 9.7% (England +6.0%, Spelthorne +9.3%) and stroke prevalence fell 0.4% (England +2.3%), while smoking cessation support offered dropped 8.5 pp to 88.4% (England +0.1 pp, 94.2%). In contrast, heart failure reviews rose 19.3% (England +8.7%) to reach 85.0% (England 78.5%), and statin treatment for patients with diabetes without CVD grew 17.2% (England +2.1%). Clinical delivery on active registers remains high, but contracting registers alongside national growth could reflect diagnostic variation, which practice clinical audits would clarify.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Dementia register
Smoking support (SMI)
Alcohol record (psychosis)
COPD register
Stroke register
Diabetes statin (no CVD)
Heart failure reviews
BP check (SMI)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Spelthorne | Asset | PCN | Spelthorne |
|---|---|---|---|---|---|
| Care homes (catchment) | 12 (614 beds) | n/a | Schools (catchment) | 57 | n/a |
| Children's centres | 5 | 6 | Places of worship | 51 | 43 |
| Libraries | 4 | 1 | Homelessness support (VCS) | 0 | no data |
| Day centres (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 1 |
| Primary schools (LA maintained) | 11 | 8 | Primary academies | 6 | 8 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Heart failure register case-finding review
Recorded heart failure prevalence is 0.8% (313 of 39,674 patients) against Spelthorne 1.0% and England 1.1%, a benchmark scenario range of +90 to +123 patients. For discussion, practices could search clinical records for uncoded heart failure diagnoses, prioritising Grove Medical Centre by list size and Core20 volume. Low cost, quick to run.
Option 2
Smoking cessation support offer recovery
Smoking cessation support offered is 88.4% (Spelthorne 95.1%, ICB 94.3%, England 94.2%) after falling 8.5 pp over 2023 to 2025 (England +0.1 pp). For discussion, the PCN could standardise clinical review templates and opportunistic smoking support prompts during long-term condition reviews, starting at Grove Medical Centre. Low cost, quick to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Option 3
Vaccination and asthma recall alignment
QOF vaccination achievement spans 37.3 pp from Virginia Water Medical Practice (34.6%) to Grove Medical Centre (71.9%; England 55.2%), while 84.0% asthma reviews leave 319 of 1,993 patients unreviewed. For discussion, practices could align call-recall workflows between Grove Medical Centre and Virginia Water Medical Practice and run asthma recalls. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Culturally tailored primary care outreach (p2) | Asian / Asian British | Neighbourhood health framework · Core20PLUS5 approach | PCN |
| Targeted Core20 practice outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| Smoking cessation support recall (p4) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension blood pressure control review (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation recall audit (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening uptake review (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | Practice |
| Practice telephony and access review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Heart failure register case-finding review (p12) | Heart failure register · Heart Failure: QOF prevalence · Registered population | — | PCN |
| Option 2 · Smoking cessation support offer recovery (p12) | Smoking cessation support and treatment offered to patients with certain conditions (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Option 3 · Vaccination and asthma recall alignment (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN & Practice |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
